Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954004 · ClinicalTrials.gov registry record
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Completed
- Registry status
- 1,270
- Enrollment target
NCT01954004: Completed study, sponsored by Myriad Genetic Laboratories.
NCT01954004 is a clinical trial that has completed, run by Myriad Genetic Laboratories. The registered enrollment target is 1,270 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01954004 has completed, sponsored by Myriad Genetic Laboratories.
- COMPLETED
- Registry status
- 1,270 participants
- Enrollment target
Study Summary
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,270 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-09 |
What the finished NCT01954004 record still lists
NCT01954004 is an observational study that tracks outcomes without assigning an intervention. Its 1,270 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01954004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01954004 about?
NCT01954004 is a clinical study titled "Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients". This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
What is the current status of trial NCT01954004?
This trial is currently completed. The enrollment target is 1,270 participants. The study started on 2013-04. Estimated completion is 2014-09.
Who is sponsoring clinical trial NCT01954004?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia